ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2016.3375 ETM-0-0-3375 Articles Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice SongLei 1 2 ZhangZhongrui 1 ZhangJinling 1 ZhuXuebin 1 HeLei 1 ShiZhe 1 GaoLi 1 FengFumin 1 Key Laboratory of Coal Mine Health and Safety, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China Bayan Nur Center for Disease Control and Prevention, Bayan Nur, Inner Mongolia 015000, P.R. China Correspondence to: Professor Fumin Feng, Key Laboratory of Coal Mine Health and Safety, School of Public Health, North China University of Science and Technology, 57 Jian-She Road, Tangshan, Hebei 063000, P.R. China, E-mail: fm_feng@sina.com 08 2016 20 05 2016 12 2 889 894 16052015 15012016 Copyright: © Song et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Liver injury is a major hindrance to the treatment of tuberculosis (TB) patients due to the primary side effects associated with anti-TB drugs. Several investigations have identified sensitive biomarkers for the early diagnosis of anti-TB drug-induced liver injury (ADLI), including the use of microRNAs (miRNAs/miRs). However, the association between miR-122/155 and ADLI remains unknown. Thus, the present study used reverse transcription-quantitative polymerase chain reaction to observe changes in tissue miR-122/155 expression levels during the course of liver injury in mice. Liver injury was induced by the administration of isoniazid (INH), a first-line anti-TB drug. miR-122/155 expression levels were quantified at seven time points throughout 1 day (0.25, 0.75, 1.5, 6, 12, 18 and 24 h) based on the pharmacokinetics of INH in mice. Notably, over the timecourse of INH-induced liver injury, the tissue miR-122 expression level significantly decreased at 0.25 h, which is the peak concentration time of INH, compared with the control group (P<0.05). The change was more rapid than that of the serum aminotransferase and miR-155, which were significantly increased at 0.75 h. In addition, the pathological score correlated with the ratio of miR-122/miR-155 (r=−0.779; P<0.01). In conclusion, the miR-122/155 ratio may be utilized as a sensitive biomarker for ADLI, which could contribute to the early diagnosis of patients following anti-TB treatment.

 antituberculosis drug-induced liver injury epigenetics microRNAs microRNA-122 microRNA-155 isoniazid Introduction

Tuberculosis (TB), which is a chronic infectious disease caused by Mycobacterium tuberculosis, is a global burden, with 8.7 million new cases and 1.4 million mortalities reported in 2011 (1). Anti-TB drug-induced liver injury (ADLI) is a severe adverse effect of TB treatment and may negatively affect treatment compliance.

Isoniazid (INH) is a first-line therapy for the treatment of TB, however, hepatotoxicity is a frequently observed side effect of INH that may progress into liver cirrhosis (2).

The current biomarkers for liver injury [serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] are adequate indicators of damage or altered liver function (3). However, the aforementioned parameters are unable to conclusively identify liver injury. In addition, serum ALT and AST activity also increase following the injury of other organs, and therefore are not selective for liver injury (4). Thus, gene expression variations are preferable for the classification of hepatotoxicants (5). Our previous study used epigenetics to identify that DNA methylation is a more sensitive marker for the detection of ADLI (6). Furthermore, recent studies have revealed that microRNA (miRNA/miR) may be used as a novel biomarker for mRNA regulatory genes (7,8).

miRNAs are small (18–25 nt) endogenous, non-coding RNA molecules that regulate post-transcriptional gene expression through RNA interference, or through inhibition of translational initiation and progression (9). Over 30% of mammalian genes are regulated by miRNA (10); therefore, miRNAs are important in a wide variety of physiological and pathological processes (11). It has been reported that miRNA expression levels differ significantly in various diseases, indicating the potential for their use as biomarkers (12–14).

Among miRNAs, miR-122, which accounts for ~70% of the total miRNA in the adult liver, is associated with liver biology and disease, including cell cycle progression, hepatocellular carcinogenesis (15), lipid metabolism (16) and fibrosis (17). Furthermore, miR-122 has been confirmed as a potential biomarker for the diagnosis of hepatotoxicity caused by acetaminophen (18) and alcohol (19). In addition, miR-155 is a multi-functional miRNA known to have a regulatory role in numerous biological processes, including immunity (20), inflammation (21), atherosclerosis (22) and cancer (23). However, it has been demonstrated that liver tissue miR-155 expression levels are increased in non-alcoholic steatohepatitis and hepatocellular carcinoma, and the expression levels were associated with disease severity (24,25). These findings suggest a strong association between the miR-122/155 ratio and liver injury. Although much is known concerning the effects of liver injury, information on miR-122/155 expression and ADLI remains limited.

miR-122/155 regulate a large number of genes and consequently are involved in numerous biological processes, including the response to environmental chemicals. Therefore, the present study hypothesized that the levels of miR-122/155 in the liver tissue and blood may serve as a biomarker for ADLI. Consequently, miR-122/155 expression levels in the liver tissue of mice with INH-induced ADLI were analyzed to identify changes in miR-122/155 expression levels over a 24-h period. The aim of this was to confirm the effectiveness of the miR-122/155 ratio as quantitative marker for ADLI.

 Materials and methods <sec> <title>Animals

A total of 64 Kunming mice (32 males and 32 females; 5 weeks old; body weight, 18–22 g; certificate no. 2009–0004) were obtained from Beijing HFK Bioscience Co., Ltd. (Beijing, China). The present study was approved by the ethics committee of North China University of Science and Technology (Tangshan, China). To establish the ADLI models, mice were orally administered INH (0.2 ml/mouse; 180 mg/kg body weight; Shenyang Hongqi Pharmaceutical Co., Ltd., Liaoning, China; batch no. 1204081) dissolved in double-distilled water (ddH20) to a final concentration of 18 mg/ml. Blood and liver tissue samples were collected at 0.25, 0.75, 1.5, 6, 12, 18 and 24 h following the administration of INH or ddH20 (control group; n=8 per time point/group). In order to harvest the liver, the mice were sacrificed by cervical dislocation. The blood samples were centrifuged at 1,370 × g for 10 min at 4°C, and the serum was collected and stored at −80°C until use. A section of the liver from the porta hepatis was fixed in 10% neutral buffered formalin (Tianjin Kemiou Chemical Reagent Co., Ltd., Tianjin, China) and the remaining liver was preserved at −80°C.

 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from the livers of mice using a benchtop homogenizer (no. TGL-16B; Shanghai Anting Scientific Instrument Factory, Shanghai, China) with TRIzol® reagent (cat no. 15596-018; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocol. The total RNA concentration was quantified using a UV-VIS spectrophotometer (product no. TU-1901; Beijing Purkinje General Instrument Co., Ltd. Beijing, China). The RNA quality and integrity was assessed by measuring the absorbance ratio at 260 and 280 nm, and by performing 1% agarose gel electrophoresis. RNA was reverse transcribed into cDNA using miR-122/155 and U6-specific RT primers and the TaqMan MicroRNA Reverse Transcription kit (product no. 4366596; Applied Biosystems; Thermo Fisher Scientific, Inc.) on a C1000 Touch Thermo Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA), according to the manufacturer's protocols. The cycling conditions for the RT reaction were as follows: 16°C for 30 min, 42°C for 30 min, 85°C for 5 min and 4°C for 1 min. The presence of miR-122/155 was confirmed using Platinum SYBR Green qPCR SuperMix-UDG (cat no. 11733-038; Invitrogen; Thermo Fisher Scientific, Inc, Waltham, MA, USA) on a StepOnePlus Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). U6 small nuclear RNA (snRNA) was used as the miRNA internal control. The primers were designed using Primer Premier software (version 5.0; Premier Biosoft International, Palo Alto, CA, USA) and were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). The primer and probe sequences for the RT-qPCR are presented in Table I. The PCR cycling conditions were as follows: 50°C for 1 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Relative miRNA production was calculated using the 2−∆∆Cq method (26), where Cq is the quantification cycle. All reactions were run in triplicate, and the results were normalized to U6 snRNA.

 Biochemical assay and pathological examination

Serum ALT and AST levels were determined using an automatic biochemical analyzer (no. 7180; Hitachi, Tokyo, Japan), according to the manufacturer's protocol. Formalin-fixed samples were embedded in paraffin, sectioned (4-µm thickness), and stained with hematoxylin and eosin (H&E; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for microscopic examination (CX21; Olympus Corporation, Tokyo, Japan). The degree of liver tissue injury was determined using a semi-quantitative method (27), in which the liver lesion severity number was multiplied by the weighted coefficient. The liver lesion severity numbers were as follows: Hepatocellular congestion, hemorrhage, 1; hepatocyte degeneration water, 1; inflammatory cell infiltration, 1; and hepatocyte necrosis, 3. The degree of liver injury was then calculated.

 Statistical analysis

The data are expressed as the mean ± standard deviation. Statistical differences between groups were determined using Students t-tests. Multiple group comparisons were performed using analysis of variance in combination with a Tukey's or Dunnett's post-hoc test. Statistical analyses were conducted using SPSS software, version 17 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Histopathology and biochemistry of mouse liver

Histological examinations were performed on liver specimens (Fig. 1A-H) and the associated scores of the liver injury are displayed in Fig. 2. The livers of the INH-treated mice exhibited evidence of damaged cells from the 0.25 h time point (Figs. 1B and 2). Thus, an INH-induced liver injury model was established. Furthermore, at the 0.75 h time point, evidence of inflammatory cell infiltration was observed (Fig. 1C).

The serum ALT and AST levels (Fig. 3) were increased at different time points of INH-induced liver injury (Fig. 3). The serum ALT and AST levels were significantly higher 0.75 and 1.5 h after INH administration compared with the control group (P<0.05; Fig. 3), however, liver injury was observed from 0.25 h onwards (Fig. 2).

Thus, the present study determined that the variations in serum ALT and AST occur subsequent to the histopathological changes caused by INH-induced liver injury.

 Changes in tissue miR-122/155 expression in mice with INH-induced liver injury

miR-122/155 expression levels were observed in the mice liver the tissues over a 24-h period (Fig. 4). The miR-122 levels were significantly declined at 0.25 h, with a 56.50±27.77%-fold decrease observed compared with the control (P<0.05). Although the expression levels of miR-122 were marginally increased at the other time points, they were immediately followed by small declines in expression, and the expression levels remained lower, as compared with the control (Fig. 4A). These results suggest that miR-122 expression levels decline during INH-induced liver injury. Conversely, miR-155 levels were significantly increased at 0.75 h (11.25±1.43%-fold increase; P<0.05) and reached peak expression levels at the 12-h time point (39.04±4.10%-fold increase; P<0.01; Fig. 4B). These results suggest that tissue miR-155 expression levels are elevated during INH-induced liver injury. Notably, the expression levels of miR-122 were altered more rapidly in response to INH-induced liver injury, as compared with miR-155 (Fig. 4C).

 Correlation of pathological and biochemical changes with INH-induced liver injury

Liver injury score was correlated to changes in biochemistry over the 24-h period during INH-induced liver injury. An association was observed between liver injury score and the following: miR-122 expression, miR-155 expression, the ratio of miR-122/155 and the ratio of miR-155/122, in which the ratio of miR-122/155 exhibited the most significant correlation (r=−0.779; P<0.001). However, liver injury scores revealed no correlation with ALT or AST. In conclusion, the ratio of miR-122/155 has a greater degree of correlation with liver damage compared with ALT, AST, miR-122 and miR-155 expression (Table II).

 Discussion

miRNAs are important in a wide variety of physiological and pathological processes (28). Recently, miRNAs have been revealed as potential biomarkers for the diagnosis of several diseases. In the present study, tissue miR-122 was examined as a potential marker of hepatocyte damage, and miR-155 as a marker of inflammation in INH-induced liver injury. A mouse model of INH-induced liver injury was established and changes in tissue miR-122/155 expression levels at different time points during liver injury were analyzed.

Changes in miR-122/155 expression levels in INH-induced liver injury were recorded at seven time points (0.25, 0.75, 1.5, 6, 12, 18 and 24 h) based on the known pharmacokinetics of INH in mice (29). Double the recommended dosage for humans for was administered to replicate the initial dosing administered to humans in clinical treatment. The present study identified that tissue miR-122/155 expression levels significantly changed during liver injury. Compared with the control group, tissue miR-122 expression levels decreased during INH-induced liver injury. In a previous study involving the use of a mouse model administered with acetaminophen, miR-122 expression levels in the tissue were also observed to decrease (30). The aforementioned study also indicated that the damaged cells within the liver tissue resulted in the transport or release of cellular miRNAs into the peripheral circulation (30). Notably, in the present study, tissue miR-122 expression levels initially decreased and initiated two upward trends after 0.25 h and 1.5 h. The aforementioned change may be a result of the pharmacokinetics of INH, as the peak concentration times of INH and its metabolite hydrazine, which are the primary chemical substances that give rise to INH-induced liver injury, are 0.25 h and 1.5 h, respectively (29). As the peak concentration times correspond to the increase in miR-122 expression levels, we hypothesize that there may be an association between miR-122 and the peak concentration times of INH; however, further investigation is required.

The target genes of miR-155, including interleukin-1 and v-ets avian erythroblastosis virus E26 oncogene homolog 1, are associated with the immune and hematopoietic systems (31,32). To investigate the role of miR-155 during liver injury, the present study examined the dynamic changes in miR-155 expression levels in the livers of mice with INH-induced liver injury. Liver tissues were observed under a microscope with H&E staining to investigate the inflammatory response at 0.25 h. miR-155 expression levels displayed an overall upward trend in the present study, suggesting that tissue miR-155 expression levels increase during inflammatory responses, reaching peak levels at 12 h and declining thereafter. Notably, the changes in miR-155 expression occur later than those of miR-122, which may be a result of the complex internal environment. An association between miR-155 and inflammatory factors was also observed in the present study. miR-155 has previously been demonstrated to promote autoimmune inflammation in inflammatory responses (33) and is upregulated in macrophages following stimulation by affecting inflammatory mediators (34). A further study determined that miR-155 was able to influence tumor necrosis factor-α expression levels to increase inflammatory injury through adjusting fas-associated death domain and inhibitor of κB expression (35). Furthermore, it was revealed that inflammatory mediators and miR-155 can influence one another's expression levels (36).

Currently, elevated serum levels of ALT and AST are used as a diagnosis of liver injury; however, their levels are also increased in other diseases, and differences in the levels of ALT and AST may occur later in the serum, as compared with the liver (37). Previous studies have demonstrated that miR-122 expression levels have a greater association with liver injury than serum ALT and AST levels; thus, miR-122 is a potential biomarker for the diagnosis of liver injury (38). In the current study, changes in miR-122 expression levels occurred prior to changes in serum ALT and AST levels. Previous evidence revealed that miR-122 is more sensitive and specific for liver injury compared with ALT and AST (18), which is consistent with the results of the present study. In addition, where the levels of ALT and AST were returned to normal at 6 h, the expression levels of miR-122 and histopathological changes of liver tissue remained unchanged. Therefore, the levels of ALT and AST are unable to accurately reveal the histopathological changes of the liver tissue (39).

At present, the ratio of ALT/AST is used to determine the degree of liver injury. In the present study, the ratio of miR-122/155 was determined by dividing miR-122 expression levels by those of miR-155. The ratio of miR-122/155 was more closely associated with the degree of liver injury than the ALT/AST ratio. miR-122 may indicate the presence of damaged hepatocytes, possibly because miR-122 is expressed by liver cells under normal physiological conditions but declines in the event of liver cell injury (40). miR-155, as an inflammation-specific miRNA, can regulate the expression of inflammatory cells (41). The current study also reported that miR-155 expression levels increase when inflammatory cells invade the liver.

In conclusion, the present study indicates that the ratio of miR-122/155 may be a more accurate biomarker of liver damage in INH-induced acute liver injury than the ratio of ALT/AST. Further studies involving various anti-TB drugs are, however, required to consolidate upon this finding.

 Acknowledgements

The present study was supported by the Key Lab of Tangshan (grant no. 08150201A-1-8).

 References GlaziouPFalzonDFloydKRaviglioneMGlobal epidemiology of tuberculosisSemin Respir Crit Care Med34316201310.1055/s-0032-133346723460002 ShihTYYoungTHLeeHSHsiehCBHuOYProtective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicityAAPS J15753762201310.1208/s12248-013-9490-623591749 ShiQHongHSeniorJTongWBiomarkers for drug-induced liver injuryExpert Rev Gastroenterol Hepatol4225234201010.1586/egh.10.820350268 Zelber-SagiSTokerSArmonGMelamedSBerlinerSShapiraIHalpernZSantoEShiboletOElevated alanine aminotransferase independently predicts new onset of depression in employees undergoing health screening examinationsPsychol Med4326032613201310.1017/S003329171300050023522007 YangXGreenhawJShiQSuZQianFDavisKMendrickDLSalminenWFIdentification of urinary microRNA profiles in rats that may diagnose hepatotoxicityToxicol Sci125335344201210.1093/toxsci/kfr32122112502 ZhangBSunSShenLZuXChenYHaoJHuangXFengFDNA methylation in the rat livers induced by low dosage isoniazid treatmentEnviron Toxicol Pharmacol32486490201110.1016/j.etap.2011.07.00122004970 DuskovaKNagillaPLeHSIyerPThalamuthuAMartinsonJBar-JosephZBuchananWRinaldoCAyyavooVMicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell countsBMC Infect Dis3250201310.1186/1471-2334-13-250 MiSLZhangJZhangWHuangRSCirculating microRNAs as biomarkers for inflammatory diseasesMicrorna26472201310.2174/2211536611302010007 HendersonMCAzorsaDOThe genomic and proteomic content of cancer cell-derived exosomesFront Oncol238201210.3389/fonc.2012.0003822649786 LewisBPBurgeCBBartelDPConserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targetsCell1201520200510.1016/j.cell.2004.12.03515652477 WuDMurashovAKMolecular mechanisms of peripheral nerve regeneration: Emerging roles of microRNAsFront4552013 UliviPFoschiGMengozziMScarpiESilvestriniRAmadoriDZoliWPeripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLCInt J Mol Sci141033210342201310.3390/ijms14051033223681013 Sita-LumsdenADartDAWaxmanJBevanCLCirculating microRNAs as potential new biomarkers for prostate cancerBr J Cancer10819251930201310.1038/bjc.2013.19223632485 GiustiID'AscenzoSDoloVMicrovesicles as potential ovarian cancer biomarkersBioMed Res Int2013703048201310.1155/2013/70304823484144 WangBWangHYangZMiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1RPLoS One7e47053201210.1371/journal.pone.004705323056576 TsaiWCHsuSDHsuCSLaiTCChenSJShenRHuangYChenHCLeeCHTsaiTFMicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesisJ Clin Invest2228842897201210.1172/JCI63455 AratakiKHayesCNAkamatsuSAkiyamaRAbeHTsugeMMikiDOchiHHiragaNImamuraMCirculating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis BJ Med Virol8578979810.1002/jmv.2354023508904 AntoineDJDearJWLewisPSPlattVCoyleJMassonMThanacoodyRHGrayAJWebbDJMoggsJGMechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospitalHepatology58777787201310.1002/hep.2629423390034 ZhangYJiaYZhengRGuoYWangYGuoHFeiMSunSPlasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseasesClin Chem5618301838201010.1373/clinchem.2010.14785020930130 LindEFOhashiPSMir-155, a central modulator of T-cell responsesEur J Immunol441115201410.1002/eji.20134396224571026 McDanielKHerreraLZhouTFrancisHHanYLevinePLinEGlaserSAlpiniGMengFThe functional role of microRNAs in alcoholic liver injuryJ Cell Mol Med18197207201410.1111/jcmm.1222324400890 WeiYNazari-JahantighMNethPWeberCSchoberAMicroRNA-126, −145, and −155: A therapeutic triad in atherosclerosis?Arterioscler Thromb Vasc Biol33449454201310.1161/ATVBAHA.112.30027923324496 FarooqiAAQureshiMZCoskunpinarENaqviSKYaylimIIsmailMmiR-421, miR-155 and miR-650: Emerging trends of regulation of cancer and apoptosisAsian Pac J Cancer Prev1519091912201410.7314/APJCP.2014.15.5.190924716910 WangBMajumderSNuovoGKutayHVoliniaSPatelTSchmittgenTDCroceCGhoshalKJacobSTRole of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 miceHepatology5011521161200910.1002/hep.2310019711427 PogribnyIPStarlard-DavenportATryndyakVPHanTRossSARusynIBelandFADifference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, asnd miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in miceLab Invest9014371446201010.1038/labinvest.2010.11320548288 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) MethodMethods25402408200110.1006/meth.2001.126211846609 GuanTMLiuDCWangJFCaiSLinMJLuRRWuKFMaXLWuTLiWDProtective effect of extract from fruit of Clausena lansium (Lour.) Skeels against acute alcohol-induced hepatotoxicity in miceZhong Guo Yao Li Xue Yu Du Li Xue Za Zhi268298342012(In Chinese) LeHSBar-JosephZIntegrating sequence, expression and interaction data to determine condition-specific miRNA regulationBioinformatics29i89i97201310.1093/bioinformatics/btt23123813013 HouYNZhangXLWuHHEffect of rifampicin and isoniazid coadministration on the metabolism and pharmacokinetics of isoniazid in miceJie Fang Jun Yao Xue Xue Bao2723262011(In Chinese) WangKZhangSMarzolfBTroischPBrightmanAHuZHoodLEGalasDJCirculating microRNAs, potential biomarkers for drug-induced liver injuryProc Natl Acad Sci USA10644024407200910.1073/pnas.081337110619246379 CeppiMPereiraPMDunand-SauthierIBarrasEReithWSantosMAPierrePMicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cellsProc Natl Acad Sci USA10627352740200910.1073/pnas.081107310619193853 LuFWeidmerALiuCGVoliniaSCroceCMLiebermanPMEpstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistenceJ Virol821043610443200810.1128/JVI.00752-0818753206 KuoYCLiYSZhouJShihYRMillerMBroideDLeeOKChienSHuman mesenchymal stem cells suppress the stretch-induced inflammatory miR-155 and cytokines in bronchial epithelial cellsPLoS One8e71342201310.1371/journal.pone.007134223967196 Nazari-JahantighMWeiYNoelsHAkhtarSZhouZKoenenRRHeyllKGremseFKiesslingFGrommesJMicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophagesJ Clin Invest12241904202201210.1172/JCI6171623041630 TiliEMichailleJJCiminoACostineanSDumitruCDAdairBFabbriMAlderHLiuCGCalinGACroceCMModulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shockJ Immunol17950825089200710.4049/jimmunol.179.8.508217911593 MillerAMGilchristDSNijjarJAraldiERamirezCMLaveryCAFernández-HernandoCMcInnesIBKurowska-StolarskaMMiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in micePLoS One8e72324201310.1371/journal.pone.007232423991091 SeniorJRAlanine aminotransferase: A clinical and regulatory tool for detecting liver injury-past, present, and futureClin Pharmacol Ther92332339201210.1038/clpt.2012.10822871997 YamauraYNakajimaMTakagiSFukamiTTsuneyamaKYokoiTPlasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosisPLoS One7e30250201210.1371/journal.pone.003025022363424 AnFMYuDSXieQGongBDWangHGuoQYuHThe role of miR-122 expression during the acute liver failure in mice induced by D-GalN/LPSZhonghua Gan Zang Bing Za Zhi185275322010(In Chinese)20678445 JoplingCLiver-specific microRNA-122: Biogenesis and functionRNA Biol9137142201210.4161/rna.1882722258222 WagnerAEBoesch-SaadatmandiCDoseJSchultheissGRimbachGAnti-inflammatory potential of allyl-isothiocyanate - role of Nrf2, NF-(k) B and microRNA-155J Cell Mol Med16836843201210.1111/j.1582-4934.2011.01367.x21692985

Representative hematoxylin and eosin-stained liver sections from (A) control mice and mice treated with isoniazid (180 mg/kg) for (B) 0.25, (C) 0.75, (D) 1.5, (E) 6, (F) 12, (G) 18 and (H) 24 h (original magnification, ×100).

Liver injury score of 80 mice at various time points throughout a 24-h period following the oral administration of INH (180 mg/kg). The liver injury score was determined by a semi-quantitative method. Data are presented as mean ± standard deviation. *P<0.05 vs. control.

Serum ALT and AST levels in 80 mice at various time points throughout a 24-h period following the oral administration of INH (180 mg/kg). The levels of ALT and AST were determined using an automatic biochemical analyzer. Data are presented as mean ± standard deviation. *P<0.05 vs. control. ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Relative (A) miR-122 and (B) miR-155 expression levels in 80 mice at various time points throughout a 24-h period following the oral administration of INH (180 mg/kg). (C) A comparison of the expression levels of miR-122 and miR-155 in response to INH-induced liver injury. Abundance of miR-122 and miR-155 was measured by reverse transcription-quantitative polymerase chain reaction following normalization with U6 small nuclear RNA. Data are presented as mean ± standard deviation. *P<0.05, **P<0.01 vs. control. miR, microRNA.

RT-qPCR primer and probe sequences.

Gene Primer/Probe
RT
  miR-122 5′-ACAATGGTGTTTGTGTCCAAACCACAAACACCATTGTCA-3′
  miR-155 5′-ATAGGGGTTTTGGCCTCTGACTGACTCCTAATCACAATTAGC-3′
  U6 5′-ATGGAACGCTTCACGAATTTGCGTGTCATCC-3′
qPCR
  miR-122 F: 5′-GCAGCTGTGGAGTGACAATGG-3′
  miR-155 F: 5′-GCCTGTTAAGCTAATTGTGAT-3′
  miR-122/155 R: 5′-GTGCAGGGTCCGAGGT-3′
  U6 F: 5′-GCAAGGATGACACGCAAT-3′
R: 5′-ATGGAACGCTTCACGAAT-3′

RT-qPCR, reverse transcription-quantitative polymerase chain reaction; miR, microRNA; F, forward; R, reverse.

Association between pathological changes and liver injury score.

Liver injury score correlation ALT AST miR-122 miR-155 miR-122/miR-155
r-value 0.157 0.053 −0.592 0.678 −0.779
P-value 0.215 0.678 0.001a 0.001a 0.001a

P<0.05 vs. the control. ALT, alanine aminotransferase; AST, aspartate aminotransferase; miR, microRNA.